anti-TNFSF12 (TNFSF12) Antikörper

Auf www.antikoerper-online.de finden Sie aktuell 145 Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12) Antikörper von 24 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen TNFSF12 Kits (32) und TNFSF12 Proteine (32) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 218 TNFSF12 Produkte verfügbar.
Synonyme:
Apo3l, Dr3l, Dr3lg, Tweak
Alle Antikörper anzeigen Gen GeneID UniProt
TNFSF12 8742 O43508
TNFSF12 21944 O54907
TNFSF12 360548  

Meistgesuchte Reaktivitäten zu anti-TNFSF12 (TNFSF12) Antikörper

anti-Human TNFSF12 Antikörper:

anti-Mouse (Murine) TNFSF12 Antikörper:

anti-Rat (Rattus) TNFSF12 Antikörper:

Alle verfügbaren anti-TNFSF12 Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Weitere Antikörper gegen TNFSF12 Interaktionspartner

Human Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12) Interaktionspartner

  1. Plasma TWEAK levels do not reflect disease activity or the grade of inflammation in patients with newly diagnosed inflammatory bowel disease.

  2. TWEAK may contribute to the pathogenesis of BP by reducing BP180 (zeige COL17A1 Antikörper) expression and cellular adherence, involving the activation of ERK (zeige EPHB2 Antikörper) and NF-kappaB (zeige NFKB1 Antikörper) pathways. TWEAK may serve as a biomarker or therapeutic target of BP.

  3. TWEAK upregulated the expression of Fn14 (zeige TNFRSF12A Antikörper).

  4. Fn14 (zeige TNFRSF12A Antikörper) plays a protective role during the acute stages of intestinal inflammation, and its absence promotes the development of colitis-associated cancer.

  5. Fn14 (zeige TNFRSF12A Antikörper).TRAIL can be converted into a highly effective TRAIL oligomer upon binding to TWEAK which induces lymphoblast apoptosis.

  6. Data show that aurintricarboxylic acid (ATA) targets the TNF-related WEAK inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (zeige DDX3X Antikörper) (Fn14 (zeige TNFRSF12A Antikörper)) signaling axis, which could potentially be developed as a new therapeutic agent for treatment of glioblastoma (GBM) patients.

  7. soluble Fn14 (zeige TNFRSF12A Antikörper) may serve as a potential biomarker for both acute and chronic kidney diseases.

  8. The result of transwell assay revealed that TWEAK promoted LX-2 migration. Subsequently, our data testified that the expression and activity of MMP9 (zeige MMP9 Antikörper) was induced by TWEAK in LX-2 cells, which enhanced the migration. Furthermore, our findings showed that TWEAK upregulated the phosphorylation of IkappaBalpha (zeige NFKBIA Antikörper) and p65 (zeige GORASP1 Antikörper) protein to increase MMP9 (zeige MMP9 Antikörper) expression in LX-2 cells.

  9. In this review article, we summarize studies indicating that (i) Fn14 (zeige TNFRSF12A Antikörper) gene expression is low in normal brain tissue but is upregulated in advanced brain cancers and, in particular, in GB tumors ; TWEAK: Fn14 (zeige TNFRSF12A Antikörper) engagement as well as Fn14 (zeige TNFRSF12A Antikörper) overexpression can stimulate glioma cell migration, invasion and resistance to chemotherapeutic agents in vitro.

  10. Findings suggest that TWEAK may contribute to chronic renal changes and renal fibrosis by activating TGF-beta1 (zeige TGFB1 Antikörper) signaling pathway, and phosphorylation of Smad2 (zeige SMAD2 Antikörper) and p38 MAPK (zeige MAPK14 Antikörper) proteins was also involved in this signaling pathway.

Mouse (Murine) Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12) Interaktionspartner

  1. These results implicate TWEAK as a potential molecular target for treatment or prevention of inflammatory arthritis and autoimmune diseases such as rheumatoid arthritis.

  2. soluble Fn14 (zeige TNFRSF12A Antikörper) may serve as a potential biomarker for both acute and chronic kidney diseases.

  3. Findings suggest that TWEAK may contribute to chronic renal changes and renal fibrosis by activating TGF-beta1 (zeige TGFB1 Antikörper) signaling pathway, and phosphorylation of Smad2 (zeige SMAD2 Antikörper) and p38 MAPK (zeige MAPK14 Antikörper) proteins was also involved in this signaling pathway.

  4. TWEAK/Fn14 (zeige TNFRSF12A Antikörper) signaling represses PGC-1alpha (zeige PPARGC1A Antikörper) expression during acute kidney injury through activation of canonical NF-kappaB (zeige NFKB1 Antikörper) pathways and epigenetic mechanisms including histone deacetylation on NF-kappaB (zeige NFKB1 Antikörper)-binding sites.

  5. These findings suggest that TWEAK signaling might be an aspect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -mediated neuropathology and be involved in the overall neurodegenerative pathology of Parkinson's disease

  6. results revealed that TWEAK and Fn14 (zeige TNFRSF12A Antikörper) are expressed by uterine natural killer cells in pregnant mice

  7. studies show that signaling via TWEAK is deleterious to muscle in RNA toxicity and support the demonstrated utility of anti-TWEAK therapeutics.

  8. During ischaemia, soluble CD163 (zeige CD163 Antikörper) functions as a decoy receptor for TWEAK, to regulate TWEAK-induced activation of canonical nuclear factor-kappaB and Notch (zeige NOTCH1 Antikörper) signalling necessary for myogenic progenitor cell proliferation.

  9. TWEAK/Fn14 (zeige TNFRSF12A Antikörper) interactions play an important role in the pathogenesis of neuropsychiatric lupus by increasing the accumulation of inflammatory cells in the choroid plexus, disrupting blood brain barrier integrity, and increasing neuronal damage

  10. Tweak regulates astrogliosis, microgliosis and skeletal muscle atrophy in a mouse model of amyotrophic lateral sclerosis

TNFSF12 Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is a ligand for the FN14/TWEAKR receptor. This cytokine has overlapping signaling functions with TNF, but displays a much wider tissue distribution. This cytokine, which exists in both membrane-bound and secreted forms, can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. This cytokine is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Alternative splicing results in multiple transcript variants. Some transcripts skip the last exon of this gene and continue into the second exon of the neighboring TNFSF13 gene\; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13.

Alternative names and synonyms associated with TNFSF12

  • tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12) Antikörper
  • tumor necrosis factor (ligand) superfamily, member 12 (Tnfsf12) Antikörper
  • tumor necrosis factor ligand superfamily member 12 (Tnfsf12) Antikörper
  • Apo3l Antikörper
  • Dr3l Antikörper
  • Dr3lg Antikörper
  • Tweak Antikörper

Bezeichner auf Proteinebene für TNFSF12

APO3 ligand , APO3/DR3 ligand , TNF-related WEAK inducer of apoptosis , tumor necrosis factor ligand superfamily member 12 , tumor necrosis factor superfamily member 12 , TNF-related weak inducer of apoptosis

GENE ID SPEZIES
8742 Homo sapiens
100568280 Canis lupus familiaris
21944 Mus musculus
360548 Rattus norvegicus
Ausgewählte Anbieter für anti-TNFSF12 (TNFSF12) Antikörper
Haben Sie etwas anderes gesucht?